Financials Pharmaniaga

Equities

End-of-day quote BURSA MALAYSIA Other stock markets 06:00:00 2024-06-11 pm EDT			5-day change	1st Jan Change
0.37 ^MYR	-2.63%		+2.78%	-3.90%

Jun. 05	Pharmaniaga Shareholders OK Renewal of Share Buyback, Transaction Mandates	MT
May. 27	Pharmaniaga Berhad Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	538.1	1,309	969.4	713.9	554.9	547.7	-
Enterprise Value (EV) ¹	538.1	1,309	969.4	713.9	554.9	547.7	547.7
P/E ratio	-3.6 x	47.6 x	5.63 x	-1.18 x	-6.8 x	10.6 x	10.9 x
Yield	4.13%	2.2%	12.6%	3.49%	-	-	-
Capitalization / Revenue	0.19 x	0.48 x	0.2 x	0.2 x	0.16 x	0.16 x	0.15 x
EV / Revenue	0.19 x	0.48 x	0.2 x	0.2 x	0.16 x	0.16 x	0.15 x
EV / EBITDA	4.12 x	12.9 x	2.83 x	-1.41 x	14.1 x	3.05 x	2.99 x
EV / FCF	4.64 x	-31.1 x	-10.3 x	-3.54 x	-59.7 x	19 x	15.8 x
FCF Yield	21.6%	-3.21%	-9.74%	-28.2%	-1.68%	5.26%	6.32%
Price to Book	1.59 x	3.88 x	2.15 x	-2.87 x	-1.78 x	-2.18 x	-2.64 x
Nbr of stocks (in thousands)	1,306,149	1,308,529	1,309,959	1,309,959	1,441,230	1,441,230	-
Reference price ²	0.4120	1.000	0.7400	0.5450	0.3850	0.3700	0.3700
Announcement Date	2/20/20	3/17/21	2/17/22	2/27/23	2/29/24	-	-

¹MYR in Million²MYR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	2,821	2,725	4,815	3,511	3,404	3,507	3,577
EBITDA ¹	130.6	101.2	342.3	-505.3	39.24	179.5	183.1
EBIT ¹	-153	68.86	308.9	-541.7	-5.106	140.3	137
Operating Margin	-5.42%	2.53%	6.41%	-15.43%	-0.15%	4%	3.83%
Earnings before Tax (EBT) ¹	-191.9	35.79	277.1	-580.8	-62.82	79.4	76.4
Net income ¹	-149.2	27.49	172.2	-607.3	-77.45	50.6	48.7
Net margin	-5.29%	1.01%	3.58%	-17.3%	-2.28%	1.44%	1.36%
EPS ²	-0.1144	0.0210	0.1315	-0.4636	-0.0566	0.0350	0.0340
Free Cash Flow ¹	116	-42.04	-94.44	-201.6	-9.295	28.8	34.6
FCF margin	4.11%	-1.54%	-1.96%	-5.74%	-0.27%	0.82%	0.97%
FCF Conversion (EBITDA)	88.83%	-	-	-	-	16.04%	18.9%
FCF Conversion (Net income)	-	-	-	-	-	56.92%	71.05%
Dividend per Share ²	0.0170	0.0220	0.0930	0.0190	-	-	-
Announcement Date	2/20/20	3/17/21	2/17/22	2/27/23	2/29/24	-	-

¹MYR in Million²MYR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow ¹	116	-42	-94.4	-202	-9.3	28.8	34.6
ROE (net income / shareholders' equity)	-35.2%	8.14%	43.7%	-	-	-	-
ROA (Net income/ Total Assets)	-8.53%	1.73%	8.97%	-29.8%	-4.13%	2.6%	2.4%
Assets ¹	1,750	1,586	1,919	2,038	1,875	1,946	2,029
Book Value Per Share ²	0.2600	0.2600	0.3400	-0.1900	-0.2200	-0.1700	-0.1400
Cash Flow per Share	-	-	-	-	-	-	-
Capex	72.7	9.25	30.4	59.3	-	-	-
Capex / Sales	2.58%	0.34%	0.63%	1.69%	-	-	-
Announcement Date	2/20/20	3/17/21	2/17/22	2/27/23	2/29/24	-	-

¹MYR in Million²MYR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.37 MYR

Average target price

0.34 MYR

Spread / Average Target

-8.11%

	1st Jan change	Capi.
PHARMANIAGA	-3.90%	116M
MCKESSON CORPORATION	+25.82%	76.86B
CARDINAL HEALTH, INC.	-2.16%	24.12B
SINOPHARM GROUP CO. LTD.	+5.87%	8.71B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+11.36%	8.57B
HUADONG MEDICINE CO., LTD	-23.95%	7.67B
H. LUNDBECK A/S	+15.02%	5.25B
GALENICA AG	+1.51%	4.12B
EBOS GROUP LIMITED	-8.25%	3.88B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+17.02%	3.55B